相关实验视频

Updated: May 24, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

SLC16A13下调有助于诱导A549肺癌细胞系A549肺亡

Aysan Zeinolabedini¹, Habib Zarredar¹, Venus Zafari²

¹Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Asian Pacific journal of cancer prevention : APJCP

|March 1, 2025

概括

减少肺癌细胞中的溶性载体家族16成员1 (SLC16A13) 表达,可以促进细胞亡并降低活力. 这表明SLC16A13是非小细胞肺癌治疗的潜在治疗标.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症新陈代谢癌症新陈代谢

背景情况:

非小细胞肺癌 (NSCLC) 是全球癌症死亡的主要原因.
参与细胞代谢的溶液载体蛋白 (SLC) 越来越多地被认为是癌症中的作用.
溶性载体家族16成员1 (SLC16A13) 载体已经成为促进癌症的潜在参与者.

研究的目的:

为了研究SLC16A13表达减少在A549肺癌细胞中的功能影响.
探索SLC16A13在调节癌细胞活力,增殖和亡中的作用.
通过针对SLC16A13.3来确定NSCLC的潜在治疗策略.

主要方法:

培养A549肺癌细胞系.
用SLC16A13sh-RNA感染细胞以抑制基因表达.
使用MTT测试评估细胞活力.
通过流细胞计分析亡速率.
使用实时PCR量化基因表达变化.

主要成果:

抑制SLC16A13显著增加了肺癌细胞的亡率.
减少SLC16A13表达导致癌细胞活力下降.
SLC16A13下调调节了上调调节的亲细胞亡标记物 (Bax,Caspase-3,Caspase-9) 和下调调节的抗细胞亡标记物 (Bcl-2).
通过SLC16A13抑制,E-cadherin表达没有受到影响.

结论:

SLC16A13在调节肺癌细胞的亡和活力方面发挥着作用.
准SLC16A13为诱导NSCLC细胞死亡提供了一个有希望的策略.
调节SLC16A13表达可能为肺癌治疗提供新的治疗途径.

关键词:

细胞灭亡 (apoptosis) 是一种死亡的过程.Bcl-2 的使用方法.肺癌是一种肺癌.在 SLC16A1313 中.

更多相关视频

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer

Published on: February 9, 2024

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

相关概念视频

The Intrinsic Apoptotic Pathway

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...

The Extrinsic Apoptotic Pathway

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...

Receptor Downregulation in MVBs

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...